Overview
Immune-targeting peptides occupy a unique position in the research landscape: Thymosin Alpha-1 has approval in 35+ countries for hepatitis B, hepatitis C, and immune deficiency — making it one of the most clinically validated research peptides. This stands in contrast to most other research compounds where clinical data is sparse.
Thymosin Alpha-1 (TA1) — The Gold Standard
TA1 (Zadaxin) is derived from thymosin fraction 5 — a thymic extract — and promotes T-cell maturation, NK cell activity, and cytokine regulation through Toll-like receptor 2 and 9 signaling. Established indications include:
- Hepatitis B: Multiple RCTs showing improved viral clearance and liver enzyme normalization
- Hepatitis C: RCT evidence; used in combination with interferon
- Malignancy (adjunctive): Studies in lung cancer and other malignancies showing improved immune response to therapy
- COVID-19: Multiple trials from China and Italy during the pandemic showing reduced mortality in severe COVID
Why it’s not FDA-approved: Zadaxin’s manufacturer (SciClone Pharmaceuticals) pursued approval in Asian and European markets where hepatitis B burden was higher. FDA approval was not pursued for the US market. This is a commercial, not safety, decision.
Access: Available as a research chemical in the US; approved drug in China, Italy, Philippines, and 35+ others.
GHK-Cu — Anti-Inflammatory Remodeling
Copper peptide GHK-Cu modulates inflammatory gene expression, promoting resolution of inflammation and transition to tissue repair. Loren Pickart’s research documented effects on hundreds of inflammation-related genes. Topical use is well-established; systemic use is research-stage.
Selank — Anxiety-Immune Axis
Selank’s tuftsin-derived structure gives it immune-modulatory properties alongside anxiolytic effects. Tuftsin is a natural tetrapeptide fragment of IgG that activates macrophages and NK cells. Selank’s immune effects are documented in animal and limited human research.
The Immune Modulation Distinction
“Immune support” can mean very different things:
- Immunostimulation: Enhancing immune response (TA1’s primary effect in infection and cancer)
- Immunomodulation: Balancing Th1/Th2, reducing autoimmune dysregulation (TA1’s mechanism in autoimmune contexts)
- Anti-inflammatory: Reducing inflammatory cytokines (GHK-Cu, BPC-157)
- Adaptogenic immune effects: Selank, Semax — stress-immune axis modulation
These are distinct mechanisms requiring different evidence evaluation.
Evidence Table
| Compound | Immune Effect | Evidence Level | Human Data |
|---|---|---|---|
| Thymosin Alpha-1 | T-cell maturation, NK activation | EL1-2 | Multiple RCTs (hepatitis, cancer) |
| GHK-Cu | Anti-inflammatory gene modulation | EL3 | Cell/animal primarily |
| Selank | Macrophage/NK activation (tuftsin) | EL3 | Limited human, Russia |
| BPC-157 | Anti-inflammatory, gut immunity | EL3 | Animal models |